Methotrexate: Still the anchor drug in RA treatment

Joint Bone Spine

Volumn 76, Issue 5, 2009, Pages 452-454

  Bijlsma, Johannes W J ^a   Jacobs, Johannes W G ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Anchor drug; Methotrexate; Rheumatoid arthritis; Tight control

Indexed keywords

ADALIMUMAB; ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; CREATININE; ETANERCEPT; FOLIC ACID; GLUCOCORTICOID; GLUCOSE; METHOTREXATE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALCOHOL CONSUMPTION; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD CELL COUNT; BREAST FEEDING; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; DERMATOMYOSITIS; DISEASE ACTIVITY; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG MONITORING; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDITORIAL; GASTROINTESTINAL SYMPTOM; GIANT CELL ARTERITIS; GLUCOSE BLOOD LEVEL; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID PEROXIDATION; LIVER TOXICITY; LUNG TOXICITY; MONOTHERAPY; PANCYTOPENIA; PATIENT ASSESSMENT; PATIENT EDUCATION; PATIENT MONITORING; PRACTICE GUIDELINE; PREGNANCY; PREGNANCY TEST; PSORIATIC ARTHRITIS; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; SEROLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; THORAX RADIOGRAPHY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION;

ADMINISTRATION, ORAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; EVIDENCE-BASED MEDICINE; FATIGUE; HUMANS; METHOTREXATE; NETHERLANDS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70449561631     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2009.05.007     Document Type: Editorial

References (19)

1. Combe B., Landewe R., Lukas C., et al. EULAR recommendations for the management of early arthritis: report of a task force of the ESCISIT. Ann Rheum Dis 66 (2007) 34-45
2. Bijlsma J.W., and Weinblatt M.E. Optimal use of methotrexate: the advantages of tight control. Ann Rheum Dis 66 (2007) 1409-1410
3. Sany J., Anaya J.M., Lussiez V., et al. Treatment of rheumatoid arthritis with methotrexate: a prospective open long-term study of 191 cases. J Rheumatol 18 (1991) 1323-1327
4. van Jaarsveld C.H., Jahangier Z.N., Jacobs J.W., et al. Toxicity of anti-rheumatic drugs in a randomized clinical trial of early rheumatoid arthritis. Rheumatology (Oxford) 39 (2000) 1374-1382
5. Suarez-Almazor ME, Belseck E, Shea B, et al. Methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 2000; CD000957.
6. Visser K, Katchamart W, Loza E, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E initiative. Ann Rheum Dis 2009;68:1081-2.
7. O'Dell J.R. Treating rheumatoid arthritis early: a window of opportunity?. Arthritis Rheum 46 (2002) 283-285
8. VanderHeide A., Jacobs J.W., Bijlsma J.W., et al. The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized controlled trial. Ann Intern Med 124 (1996) 699-707
9. Mottonen T., Hannonen P., Leirisalo-Repo M., et al. Comparison of combination therapy with single drug therapy in early RA: a randomized trial. FINRACo trial group. Lancet 353 (1999) 1568-1573
10. VanEverdingen A.A., Jacobs J.W., Siewertsz van Reesema D.R., et al. Low dose prednisone therapy for patients with early active RA: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo controlled clinical trial. Ann Intern Med 136 (2002) 1-12
11. Smolen J.S., Aletaha D., Koeller M., et al. New therapies for treatment of rheumatoid arthritis. Lancet 370 (2007) 1861-1874
12. Verstappen S.S.M., Jacobs J.W.G., van der Veen M.J., et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 66 (2007) 1443-1449
13. Klareskog L., vander Heijde D., de Jager J.P., et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with RA: double blind randomised controlled trial. Lancet 363 (2004) 675-681
14. Breedveld F.C., Weisman M.H., Kavanaugh A.F., et al. The PREMIER study: a multicenter, randomized, doubleblind clinical trial of combination therapy with adalumimab plus methotrexate versus methotrexate alone or adalumimab alone in patients with early aggressive RA who had no previous methotrexate treatment. Arthritis Rheum 54 (2006) 26-37
15. Hoes J.N., Jacobs J.W., Boers M., et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 66 (2007) 1560-1567
16. Mahr A.D., Jover J.A., Spiera R.F., et al. Adjunctive MTX for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 56 (2007) 2789-2797
17. Katchamart W., Ortiz Z., Shea B., et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Arthritis Rheum 58 (2008) S437
18. Salliot C., and van der Heijde D. Long term safety of Methotrexate monotherapy in rheumatoid arthritis patients: A systematic literature research. Ann Rheum Dis (2008) 10.1136/ard.2008.093690
19. Pavy S., Constantin A., Pham T., et al. Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine 73 (2006) 388-395